Allen Haddix, MD
Family Medicine · Frankfort, KYNPI 1508933771
Payments from drug & device makers
Across 182 payments — averaging $14.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$797
- Novo Nordisk$271
- Lilly USA, LLC$240
- Pfizer$193
- Boehringer Ingelheim$188
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$124
- plus $829 from 19 others
What the payments were for
- Food & beverage$2,61399%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 70 | $797 |
| Novo Nordisk | 17 | $271 |
| Lilly USA, LLC | 15 | $240 |
| Pfizer | 12 | $193 |
| Boehringer Ingelheim | 12 | $188 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $124 |
| AstraZeneca(2 entities) | 7 | $119 |
| Amgen | 5 | $95 |
| Johnson & Johnson | 5 | $91 |
| Novartis | 5 | $78 |
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
| GSK | 4 | $58 |
| E.r. Squibb & Sons, L.L.C. | 3 | $53 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| Kowa Pharmaceuticals America, Inc. | 2 | $36 |
| Astellas Pharma US Inc | 2 | $34 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Abbott | 1 | $13 |
How this compares
$2,643 in reported general payments places this provider in the 70th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 133 | $195,192 |
| XareltoRivaroxaban | 89 | $116,949 |
| FarxigaDapagliflozin Propanediol | 72 | $102,109 |
| JardianceEmpagliflozin | 74 | $96,139 |
| OzempicSemaglutide | 71 | $89,287 |
| JanuviaSitagliptin Phosphate | 50 | $79,246 |
| TrulicityDulaglutide | 36 | $57,778 |
| MounjaroTirzepatide | 42 | $53,660 |
| EntrestoSacubitril/Valsartan | 41 | $48,415 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $44,567 |
| MyrbetriqMirabegron | 24 | $22,527 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $19,981 |
| GlyxambiEmpagliflozin/Linagliptin | 11 | $19,452 |
| NexlizetBempedoic Acid/Ezetimibe | 15 | $17,818 |
| LinzessLinaclotide | 22 | $16,771 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $193 | $195,192133 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $188 | $121,05797 claims |
| Johnson & JohnsonXarelto | $91 | $116,94989 claims |
| AstraZenecaFarxiga, Symbicort | $119 | $113,838104 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $240 | $111,43878 claims |
| Novo NordiskOzempic | $271 | $89,28771 claims |
| NovartisEntresto | $78 | $48,41541 claims |
| GSKTrelegy Ellipta | $58 | $44,56742 claims |
| Astellas Pharma US IncMyrbetriq | $34 | $22,52724 claims |
| AbbVieLinzess, Synthroid | $797 | $20,565106 claims |
| Esperion Therapeutics, Inc.Nexlizet | $41 | $17,81815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Frankfort
- Anthony BarnesFrankfort$18K
- Steven CrumFrankfort$17K
- Frank FarleyFrankfort$14K
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.